A phase III study of the therapeutic lung cancer vaccine belagenpumatucel-L (Lucanix) failed to meet its predefined endpoint, but the vaccine showed a “considerable” increase in overall survival in patients with non–small-cell lung cancer.
A mutation of the PAX5 gene has been found to play an important role in inherited cases of B-cell precursor acute lymphoblastic leukemia (B-ALL). The mutation was isolated in two unrelated families with high propensity for B-ALL.
Gilead Sciences has submitted an NDA to the FDA for its new drug idelalisib, for the use in patients with indolent non-Hodgkin lymphoma that is refractory to rituximab and chemotherapy.
In order for malignancies to establish in metastatic sites, cancer cells must acquire attributes of those sites; specifically how this occurs in many cancers is relatively unknown, but a new study implicates the stroma of certain breast cancer tumors in the development of bone metastases.
Evidence continues to mount that discontinuing imatinib treatment for chronic myeloid leukemia (CML) in the chronic phase is safe. A new phase II Dutch and Belgian study showed only about two-thirds of patients relapsed after discontinuing treatment with imatinib and cytarabine, and all patients remained sensitive to imatinib after relapse.
A phase I study of dasatinib in children and adolescents with chronic myeloid leukemia (CML) and other malignancies determined dosing for further studies and suggested the drug is well tolerated and effective in these patients.
Carbon ion radiotherapy is a safe and effective method for treating unresectable spinal sarcomas, according to a retrospective analysis from one center in Japan.
Bench and mouse studies have shown that the Notch1 gene is a crucial contributor to tumorigenesis in non-small-cell lung cancer (NSCLC). It aids tumor initiation by suppressing apoptosis, or programmed cell death, which is regulated by p53.
A randomized phase III trial of adjuvant gefitinib in patients with completely resected non–small-cell lung cancer (NSCLC) was closed early, but available results suggest that the drug is unlikely to benefit this group of patients.
Maintenance therapy with rituximab showed some improvement over observation, though it did not reach significance, among older patients with advanced follicular lymphoma who responded to a brief chemoimmunotherapy induction regimen followed by rituximab consolidation therapy.